Autologous stem cell transplantation with moderate dose of Idarubicin and Busulphan as conditioning regimen in acute myelogenous leukemia

AUTHORS

MA Mashhadi 1 , * , M Ramzi 2 , K Alimoghaddam 3

1 Assistant Professor of Hematology and Oncology Unit, Department of Internal Medicine, Zahedan University of Medical Sciences, [email protected], Sistan Baloochestan, Iran

2 Hematology and Oncology Research Center, Department of Internal Medicine, Shiraz University of Medical Sciences, Fars, Iran

3 Hematology and Oncology Unit, Department of Internal Medicine, Tehran University of Medical Sciences, Tehran, Iran

How to Cite: Mashhadi M, Ramzi M, Alimoghaddam K. Autologous stem cell transplantation with moderate dose of Idarubicin and Busulphan as conditioning regimen in acute myelogenous leukemia, Iran Red Crescent Med J. Online ahead of Print ; 10(3):205-210.

ARTICLE INFORMATION

Iranian Red Crescent Medical Journal: 10 (3); 205-210
Article Type: Research Article
Received: February 14, 2008
Accepted: June 22, 2008

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Over 50% of patients with AML still relapse after autologous stem cell transplantation. We investigated the efficacy and feasibility of a new conditioning regimen consisting of a moderate dose of Idarubicine plus conventional dose of oral Busulfan in patients undergoing autologous transplantation without favorable cytogenitic state and high dose therapy with Cytarabine or other drugs.

 

Methods: Ten Patients were given three days of bolus infusion of IDA followed by four days of oral Busulfan as conditioning regimen. Unpurged peripheral blood stem cells were used in all cases. All the cases were in first complete remission (CR1).

The reasons for the selection of these patients in the first remission were that they had not received high dose chemotherapy or did not have available cytogenitic state.

 

Results: The transplant related mortality occurred in one case (refactory thrombocytopenia, leading to CNS hemorrhage). The median CD34+ cell infused was 8Ï106/kg. The median days to neutrophil recovery > (0.5 Ï 10 9) and platelet recovery > (20 Ï10 9/kg) were +9 days (4-12 days); +16 (2-30 days) respectively. The patients needed transfusion of a median of 15 platelet units and 7 blood units, respectively. Six out of 10 patients (60%) had variable grades of mucositis (three cases had grade III, two grade II and one case grade I). After a median follow up of 48 months from ASCT, 8 patients out of 10 (80%) were alive in continuous complete remission. One case had relapse after 6 months of transplantation.

 

Conclusion: The findings of the study demonstrated the efficacy and feasibility of a conditioning regimen based on a moderate dose of IDA plus Busulphan in AML. The results concerning anti-leukemic efficacy are promising but need to be confirmed on larger series.

Keywords

Acute myeloid leukemia Stem cell transplantation Idarubicin Busulphan

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: